The specific abundance of hPEBP4 in lymphoma tissues and its ability to confer rituximab resistance strongly imply that hPEBP4 could be a potential target for knockdown in the treatment of B-NHL when administered in combination with rituximab. The gene discussed is PEBP4; the disease is lymphoma.